Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Collegium Pharmaceutical Inc’s stock clocked out at $32.15, up 2.06% from its previous closing price of $31.50. In other words, the price has increased by $2.06 from its previous closing price. On the day, 0.88 million shares were traded. COLL stock price reached its highest trading level at $33.345 during the session, while it also had its lowest trading level at $31.371.
Ratios:
To gain a deeper understanding of COLL’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.41. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.84 whereas as Long-Term Debt/Eq ratio is at 2.01.
Jefferies Downgraded its Buy to Hold on January 04, 2024, whereas the target price for the stock was revised from $30 to $37.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Smith Thomas B sold 995 shares for $36.76 per share. The transaction valued at 36,580 led to the insider holds 63,409 shares of the business.
Dreyer Scott sold 10,000 shares of COLL for $364,270 on Feb 26 ’24. The EVP & Chief Commercial Officer now owns 138,918 shares after completing the transaction at $36.43 per share. On Jan 16 ’24, another insider, Dreyer Scott, who serves as the EVP & Chief Commercial Officer of the company, sold 23,560 shares for $32.28 each. As a result, the insider received 760,519 and left with 111,322 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1051796928 and an Enterprise Value of 1363740544. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.39, and their Forward P/E ratio for the next fiscal year is 4.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 24.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85 while its Price-to-Book (P/B) ratio in mrq is 4.73. Its current Enterprise Value per Revenue stands at 2.406 whereas that against EBITDA is 3.974.
Stock Price History:
The Beta on a monthly basis for COLL is 0.96, which has changed by 0.39600515 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, COLL has reached a high of $40.95, while it has fallen to a 52-week low of $20.83. The 50-Day Moving Average of the stock is -14.23%, while the 200-Day Moving Average is calculated to be 9.23%.
Shares Statistics:
It appears that COLL traded 451.25K shares on average per day over the past three months and 566900 shares per day over the past ten days. A total of 32.71M shares are outstanding, with a floating share count of 32.23M. Insiders hold about 1.47% of the company’s shares, while institutions hold 117.99% stake in the company. Shares short for COLL as of 1714435200 were 6858723 with a Short Ratio of 15.20, compared to 1711584000 on 7118018. Therefore, it implies a Short% of Shares Outstanding of 6858723 and a Short% of Float of 25.900000000000002.
Earnings Estimates
A comprehensive evaluation of Collegium Pharmaceutical Inc (COLL) is underway, with the input of 3.0 analysts contributing to its current rating.On average, analysts expect EPS of $0.96 for the current quarter, with a high estimate of $1.52 and a low estimate of $0.62, while EPS last year was $0.34. The consensus estimate for the next quarter is $1.03, with high estimates of $1.59 and low estimates of $0.69.
Analysts are recommending an EPS of between $6.18 and $2.6 for the fiscal current year, implying an average EPS of $3.75. EPS for the following year is $5.37, with 4.0 analysts recommending between $7.26 and $3.78.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $142.76M. It ranges from a high estimate of $144.8M to a low estimate of $141.05M. As of the current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $138.4MFor the next quarter, 6 analysts are estimating revenue of $144.69M. There is a high estimate of $146.93M for the next quarter, whereas the lowest estimate is $142.5M.
A total of 6 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $590.18M, while the lowest revenue estimate was $580.5M, resulting in an average revenue estimate of $583.24M. In the same quarter a year ago, actual revenue was $566.77MBased on 6 analysts’ estimates, the company’s revenue will be $594.6M in the next fiscal year. The high estimate is $605.76M and the low estimate is $579.6M.
